• Clinton J. Grubbs, Ph.D., is a basic scientist with a primary research interest in the chemoprevention of urinary bladder and mammary cancers. His major area of research is the identification of nutrient and non-nutrient agents that exhibit efficacy in the prevention of these cancers. He is a Professor in the UAB Department of Surgery and a Senior Scientist in the UAB Comprehensive Cancer Center. Dr. Grubbs received his doctoral degree from the University of Tennessee Medical Units in Memphis, Tennessee in 1973. He also completed a two year postdoctoral fellowship in biochemistry at the University of Tennessee Medical Unit. From 1975 to 1979, he was a senior physiologist at the Illinois Institute of Technology in Chicago, Illinois. After six years at Southern Research in Birmingham, he joined the faculty at UAB in the Department of Nutrition Sciences, and in 2000 transferred to the Department of Surgery.

    In 1987, he was awarded Master Agreements from the NCI for in vivo screening of chemopreventive agents and for the evaluation of the efficacy of potential preventive compounds. The agreements, now a Prime Contractor, continue to be active. Through this funding, Dr. Grubbs has established subcontracts for chemoprevention research with five universities and research institutes in the United States. Dr. Grubbs has established a national and international reputation in the preclinical evaluation of chemopreventive agents in cancer. His research is published in widely read peer-reviewed journals. At UAB, he served as Chair of the UAB IACUC Committee from 1987-2001. He also served on the PREVENT Review Panel of the National Cancer Institute for more than 10 years.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 Comparison of effects of diet on mammary cancer: Efficacy of various preventive agents and metabolomic changes of different diets and agentsCancer Prevention Research.  11:831-840. 2018
    2018 Screening of chemopreventive agents in animal models: Results on reproducibility, agents of a given class, and agents tested during tumor progressionCancer Prevention Research.  11:595-605. 2018
    2018 Corrigendum: Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models (Oncology Reports (2018) 40 (1545-1553) DOI: 10.3892/or.2018.6313)Oncology Reports.  41:718. 2018
    2018 Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer modelsOncology Reports.  40:1545-1553. 2018
    2018 A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitroJournal of Surgical Research.  228:54-62. 2018
    2018 The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axisJournal of Dermatological Science.  90:343-356. 2018
    2017 Erratum to: Mass spectrometric evidence for the modification of small molecules in a cobalt-60-irradiated rodent diet: Irradiation modifies the content of animal diet (Journal of Mass Spectrometry, (2017), 52, 8, (507-516), 10.1002/jms.3950)Journal of Mass Spectrometry.  52:707. 2017
    2017 Mass spectrometric evidence for the modification of small molecules in a cobalt-60-irradiated rodent dietJournal of Mass Spectrometry.  52:507-516. 2017
    2017 Lack of chemopreventive efficacy of metformin in rodent models of urinary bladder, head and neck, and colon/intestine cancerOncology Letters.  14:3480-3486. 2017
    2016 Translation of a tissue-selective rexinoid, UAB30, to the clinic for breast cancer preventionCurrent Topics in Medicinal Chemistry.  16. 2016
    2016 5MeCDDO blocks metabolic activation but not progression of breast, intestine, and tongue cancers. Is antioxidant response element a prevention target?Cancer Prevention Research.  9:616-623. 2016
    2016 Preclinical evaluation of UAB30 in pediatric renal and hepatic malignanciesMolecular Cancer Therapeutics.  15:911-921. 2016
    2015 Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary CancersJournal of Medicinal Chemistry.  58:7763-7774. 2015
    2015 Preclinical evaluation of a novel RXR agonist for the treatment of neuroblastomaMolecular Cancer Therapeutics.  14:1559-1569. 2015
    2015 Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse modelsCancer Prevention Research.  8:231-239. 2015
    2015 Prevention of chemically induced urinary bladder cancers by naproxen: Protocols to reduce gastric toxicity in humans do not alter preventive efficacyCancer Prevention Research.  8:296-302. 2015
    2014 Global molecular changes in rat livers treated with RXR agonists: a comparison using transcriptomics and proteomicsPharmacology Research and Perspectives.  2. 2014
    2014 Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicityJournal of Medicinal Chemistry.  57:5370-5380. 2014
    2014 Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3KCancer Prevention Research.  7:236-245. 2014
    2014 Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer modelCancer Prevention Research.  7:246-254. 2014
    2014 Effect of Withania somnifera root extract on spontaneous estrogen receptor-negative mammary cancer in MMTV/Neu miceAnticancer Research.  34:6327-6332. 2014
    2014 Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and preventionBioorganic and Medicinal Chemistry.  22:178-185. 2014
    2013 Concordant effects of aromatase inhibitors on gene expression in ER+ rat and human mammary cancers and modulation of the proteins coded by these genesCancer Prevention Research.  6:1151-1161. 2013
    2013 Diffusion Weighted Imaging Evaluated the Early Therapy Effect of Tamoxifen in an MNU-Induced Mammary Cancer Rat ModelPLoS ONE.  8. 2013
    2013 Effect of intermittent dosing regimens of erlotinib on methylnitrosourea- induced mammary carcinogenesisCancer Prevention Research.  6:448-454. 2013
    2013 Effect of an extract of Withania somnifera root on estrogen receptor-positive mammary carcinomasAnticancer Research.  33:1519-1524. 2013
    2013 Effects on gene expression in rat liver after administration of RXR Agonists: UAB30, 4-Methyl-UAB30, and Targretin (Bexarotene)sMolecular Pharmacology.  83:698-708. 2013
    2013 Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G2/M arrest and apoptosisMolecular Carcinogenesis.  52:134-143. 2013
    2012 The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathwayCancer Prevention Research.  5:810-821. 2012
    2012 Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancersOncology Reports.  27:1400-1406. 2012
    2012 Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancerCancer Prevention Research.  5:248-259. 2012
    2011 Effects of 5,6-benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: Is DIM a substitute for I3C?Oncology Reports.  26:731-736. 2011
    2011 Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathwaysCancer Prevention Research.  4:1190-1197. 2011
    2011 Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivityNahrung..  55:1249-1265. 2011
    2011 Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: Dose dependency and modulation of biomarkersOncology Reports.  25:1389-1397. 2011
    2011 Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent modelsAmerican Journal of Translational Research.  3:8-27. 2011
    2010 A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteersCancer Prevention Research.  3:1565-1570. 2010
    2010 Parity is associated with an expanded macrophage population in the mammary glandInternational Journal of Oncology.  37:1195-1202. 2010
    2010 Screening Agents for Preventive Efficacy in a Bladder Cancer Model: Study Design, End Points, and Gefitinib and Naproxen EfficacyJournal of Urology, The.  183:1598-1603. 2010
    2009 Induced expression of drug metabolizing enzymes by preventive agents: Role of the antioxidant response elementChemico-Biological Interactions.  182:22-28. 2009
    2009 Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancersCancer Prevention Research.  2:951-956. 2009
    2009 High Cks1 expression in transgenic and carcinogeninitiated mammary tumors is not always accompanied by reduction in p27Kip1International Journal of Oncology.  34:1425-1431. 2009
    2009 Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesisCancer Prevention Research.  2:161-167. 2009
    2009 Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoidCancer Biology and Therapy.  8:289-298. 2009
    2009 Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoidCancer Biology and Therapy.  8:285-294. 2009
    2008 Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancersInternational Journal of Cancer.  123:2254-2259. 2008
    2008 Effect of cranberry juice concentrate on chemically-induced urinary bladder cancersOncology Reports.  19:1565-1570. 2008
    2008 Effects of gefitinib (Iressa) on mammary cancers: Preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changesMolecular Cancer Therapeutics.  7:972-979. 2008
    2007 Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer modelClinical Cancer Research.  13:5488-5496. 2007
    2007 Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenolsMolecular Cancer Therapeutics.  6:2022-2028. 2007
    2007 Gene expression profiling of chemically induced rat bladder tumorsNeoplasia : An International Journal for Oncology Research.  9:207-221. 2007
    2006 Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: Role of Ha-ras mutations and use of microarray analysis in identifying potential targetsCarcinogenesis.  27:1420-1431. 2006
    2006 Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkersCarcinogenesis.  27:1232-1239. 2006
    2006 Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: Prevention, therapy, and role of HaRas mutationsMolecular Cancer Therapeutics.  5:1073-1078. 2006
    2006 Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4- hydroxyphenylretinamideMolecular Cancer Therapeutics.  5:1060-1072. 2006
    2005 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: Characterization of FHIT and survivin expression and chemopreventive effects of indomethacinCarcinogenesis.  26:571-578. 2005
    2005 Hypermethylation patterns in the Fhit regulatory region are tissue specificMolecular Carcinogenesis.  43:175-181. 2005
    2005 Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancerOncogene.  24:3554-3562. 2005
    2005 Efficacy of Targretin on methylnitosourea-induced mammary cancers: Prevention and therapy dose-response curves and effects on proliferation and apoptosisCarcinogenesis.  26:441-448. 2005
    2004 Proteomics analysis of rat brain protein modulations by grape seed extractJournal of Agricultural and Food Chemistry.  52:7872-7883. 2004
    2004 CpG methylation in the Fhit regulatory region: Relation to Fhit expression in murine tumorsOncogene.  23:3990-3998. 2004
    2004 Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor modelsOncogene.  23:3841-3850. 2004
    2004 Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer preventionOncology Reports.  11:465-469. 2004
    2004 Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl)nitrosamineNeoplasia : An International Journal for Oncology Research.  6:569-577. 2004
    2003 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancersCancer Letters.  201:17-24. 2003
    2003 Conformationally defined retinoic acid analogues. 5. Large-scale synthesis and mammary cancer chemopreventive activity for (2E,4E,6Z,8E)-8-(3′,4′-dihydro-1′(2′H) -naphthalen-1′-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid (9cUAB30)Journal of Medicinal Chemistry.  46:3766-3769. 2003
    2003 Chemoprevention of mammary carcinogenesis in a transgenic mouse model by α-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activityOncogene.  22:2568-2572. 2003
    2003 Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumorsBreast Cancer Research and Treatment.  77:253-264. 2003
    2003 The efficacy of 9-Cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: Results of a randomized double-blind clinical trialCancer Epidemiology, Biomarkers and Prevention.  12:114-119. 2003
    2002 Multiple comparisons model-based clustering and ternary pattern tree numerical display of gene response to treatment: Procedure and application to the preclinical evaluation of chemopreventive agentsMolecular Cancer Therapeutics.  1:1283-1292. 2002
    2002 Prevention of methylnitrosourea-induced mammary cancers by 9-cis-retinoic acid and/or vitamin D3Oncology Reports.  9:533-537. 2002
    2002 Effects of body weight gain reduction resulting from chemopreventive agent treatment on mammary gland morphologyNutrition and Cancer.  43:67-75. 2002
    2002 Paradigms for primary prevention of ovarian carcinomaCA: A Cancer Journal for Clinicians.  52:216-225. 2002
    2001 Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitorOncogene.  20:7710-7721. 2001
    2001 Effect of high retinoid doses on RAR-β mRNA expression in female B6D2F1 miceAnticancer Research.  21:1691-1695. 2001
    2001 Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesisCancer Research.  61:3961-3968. 2001
    2001 Differences in plasma and nipple aspirate carotenoid by lactation statusNursing Research.  50:172-177. 2001
    2001 Modulation of biomarkers by chemopreventive agents in smoke-exposed ratsCancer Research.  61:2472-2479. 2001
    2001 Presence of carotenoid, an anticarcinogenic marker, in nipple aspirates postlactationAdvances in Experimental Medicine and Biology.  501:143-152. 2001
    2001 Therapeutic and chemopreventive effects of R115777, a farnesyl transferase inhibitor (FTI), on methylnitrosourea (MNU)-induced rat mammary cancerBreast Cancer Research and Treatment.  69:216. 2001
    2000 Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 ratsCancer Research.  60:5599-5602. 2000
    2000 Longitudinal analysis of mammary cancer multiplicity in chemoprevention studiesAnticancer Research.  20:2281-2287. 2000
    2000 Cellular responses of mammary carcinomas to aromatase inhibitors: Effects of vorozoleBreast Cancer Research and Treatment.  60:117-128. 2000
    2000 Effects of oral administration of tamoxifen, toremifene, dehydroepiandrosterone, and vorozole on uterine histomorphology in the ratProceedings of the Society for Experimental Biology and Medicine.  223:288-294. 2000
    1999 Patterns of DNA adduct formation in liver and mammary epithelial cells of rats treated with 7,12-dimethylbenz(a)anthracene, and selective effects of chemopreventive agentsCancer Research.  59:4285-4290. 1999
    1999 Protective effects of estrogen in a rat model of age-related cataractsProceedings of the National Academy of Sciences.  96:9328-9332. 1999
    1999 A comparative analysis of allelic imbalance events in chemically induced rat mammary, colon, and bladder tumorsMolecular Carcinogenesis.  24:47-56. 1999
    1999 Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer modelCarcinogenesis.  20:71-76. 1999
    1998 Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer modelCarcinogenesis.  19:1345-1351. 1998
    1998 Anhydroretinol, a retinoid active in preventing mammary cancer induced in rats by N-methyl-N-nitrosoureaOncology Reports.  5:857-860. 1998
    1998 Retinyl substituted-benzyl ethers. Inhibition of mammary carcinogenesis by retinyl 3,4,5-trimethoxybenzyl ether (RTMBE)Anticancer Drug Design.  13:159-182. 1998
    1998 Modulation of methylnitrosourea-induced breast cancer in sprague dawley rats by dehydroepiandrosterone: Dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutationsCancer Research.  58:921-926. 1998
    1997 Hormone levels and mammary epithelial cell proliferation in rats treated with a regimen of estradiol and progesterone that mimics the preventive effect of pregnancy against mammary cancerAnticancer Research.  17:4639-4645. 1997
    1997 Chemopreventive efficacy of anethole trithione, N-acetyl-L-cysteine, miconazole and phenethylisothiocyanate in the DMBA-induced rat mammary cancer modelInternational Journal of Cancer.  72:95-101. 1997
    1997 Retinyl ethers as cancer chemopreventive agents. Suppression of mammary cancerAnticancer Drug Design.  12:15-33. 1997
    1996 Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7, 12-dimethylbenz[a]anthracene-induced mammary cancer in ratsCarcinogenesis.  17:1305-1311. 1996
    1995 Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinolAnticancer Research.  15:709-716. 1995
    1995 Effects of Dehydroepiandrosterone on MNU‐Induced Breast Cancer in Sprague‐Dawley RatsAnnals of the New York Academy of Sciences.  774:340-341. 1995
    1994 Chemopreventive effects of the aromatase inhibitors vorozole (r-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in sprague-dawley ratsCarcinogenesis.  15:2775-2780. 1994
    1994 Potential role of dietary isoflavones in the prevention of cancerAdvances in Experimental Medicine and Biology.  354:135-147. 1994
    1994 Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI chemoprevention drug development programJournal of Cellular Biochemistry.  56:32-54. 1994
    1993 Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumorsAnticancer Research.  13:33-36. 1993
    1993 The statistical analysis of cancer inhibition/promotion experimentsAnticancer Research.  13:1357-1363. 1993
    1992 Effects of folate deficiency and supplementation on methylnitrosourea-induced rat mammary tumorsJNCI: Journal of the National Cancer Institute.  84:1740-1744. 1992
    1992 Retinoids and cancer preventionAnnual Review of Nutrition.  12:161-181. 1992
    1992 Separation, purification and N-terminal sequence analysis of a novel leupeptin-sensitive serine endopeptidase present in chemically induced rat mammary tumourBiochemical Journal.  283:209-216. 1992
    1991 Effect of canthaxanthin on chemically induced mammary carcinogenesisOncology.  48:239-245. 1991
    1990 Effect of Miso (Japanese Soybean Paste) and NaCl on DMBA-Induced Rat Mammary TumorsNutrition and Cancer.  14. 1990
    1990 Effect of retinyl acetate and 4-hydroxyphenylretinamide on initiation of chemically-induced mammary tumorsAnticancer Research.  10:661-666. 1990
    1990 Soybeans inhibit mammary tumors in models of breast cancer.Progress in clinical and biological research.  347:239-253. 1990
    1988 Short-term hormone treatment as a chemopreventive method against mammary cancer initiation in ratsAnticancer Research.  8:113-117. 1988
    1986 Suppression by pregnancy of chemically induced preneoplastic cells of the rat mammary gland.Anticancer Research.  6:1395-1400. 1986
    1985 Effect of long-term administration of retinoids on rats exposed transplacentally to ethylnitrosoureaAnticancer Research.  5:205-210. 1985
    1985 Chemoprevention of N-nitroso-N-methylurea-induced mammary cancers by pretreatment with 17β-estradiol and progesteroneJNCI: Journal of the National Cancer Institute.  74:927-931. 1985
    1985 Intestinal absorption of nutrients in animals dosed orally with retinoids: Considerations for chemopreventive studiesCancer Investigation.  3:243-248. 1985
    1985 Suppression of methylnitrosourea (MNU)-induced mammary cancers by pregnancy: Elimination of preneoplastic cellsProceedings of the American Association for Cancer Research.  VOL. 26. 1985
    1983 Effect of ovarian hormones on the induction of 1-methyl-1-nitrosourea-induced mammary cancerCarcinogenesis.  4:495-497. 1983
    1983 Mammary carcinogenesis in rats in relation to age at time of N-nitroso-N-methylurea administrationJNCI: Journal of the National Cancer Institute.  70:209-212. 1983
    1983 N-nitroso-N-methylurea-induced mammary carcinogenesis: Effect of pregnancy on preneoplastic cellsJNCI: Journal of the National Cancer Institute.  71:625-628. 1983
    1982 Retinoids as chemopreventive and anticancer agents in intact animals (review)Anticancer Research.  2:111-124. 1982
    1982 Effect of age at time of 1-methyl-1-nitrosourea administration on mammary carcinogenesisProceedings of the American Association for Cancer Research.  Vol. 23. 1982
    1981 Inhibition of Urinary Bladder Cancer by N-(Ethyl)-all-frans-retinamide and N-(2-Hydroxyethyl)-all-trans-retinamide in Rats and MiceCancer Research.  41:933-936. 1981
    1981 Carcinogenicity of N-methyl-N-nitrosourea and N-ethyl-N-nitrosourea when applied to a localized area of the hamster tracheaJNCI: Journal of the National Cancer Institute.  66:961-965. 1981
    1980 Histogenesis and dose dependence of n-methyl-n-nitrosourea- induced carcinoma in a localized area of the hamster tracheaJNCI: Journal of the National Cancer Institute.  64:1135-1140. 1980
    1979 1-methyl-1-nitrosourea induction of cancer in a localized area of the Syrian golden hamster trachea.Progress in Experimental Tumor Research.  24:345-355. 1979
    1979 A quantitative dosing schedule for the induction of transitional cell carcinomas in female f344 rats with the use of n-butyl-n-(4-hydroxybutyl)nitrosamineJNCI: Journal of the National Cancer Institute.  62:187-191. 1979
    1979 Comparison of tumor induction by ethylnitrosourea and methylnitrosourea in a localized lung tumor modelProceedings of the American Association for Cancer Research.  Vol. 20:389. 1979
    1979 N-(4-Hydroxyphenyl)retinamide A New Retinoid for Prevention of Breast Cancer in the RatCancer Research.  39:1339-1346. 1979
    1979 Photooxidation products of 7,12-dimethylbenz[a] anthraceneChemico-Biological Interactions.  26:339-347. 1979
    1978 Effect of retinoids on N-methyl-N-nitrosourea (MNU)-induced mammary cancerFederation proceedings.  37. 1978
    1978 Hepatic lipocytes and storage of vitamin A analoguesFederation proceedings.  37. 1978
    1978 Induction of transitional cell carcinomas (TCC) with N-butyl-(4-hydroxybutyl)nitrosamine (OH-BBN) in female ratsProceedings of the American Association for Cancer Research.  Vol. 19. 1978
    1978 N-methyl-N-nitrosourea (MNU)-induction of tracheal cancer. A respiratory cancer model with short latency periodFederation proceedings.  37. 1978
    1977 Retinyl acetate inhibits mammary carcinogenesis induced by N-methyl-N-nitrosourea [16]Nature.  267:620-621. 1977
    1977 13-cis-retinoic acid: Inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)nitrosamineScience.  198:743-744. 1977
    1977 Inhibition of Mammary Cancer by Retinyl Methyl EtherCancer Research.  37:599-602. 1977
    1977 Suppression of NMU induced mammary cancer by vitamin A acetateProceedings of the American Association for Cancer Research.  Vol.18. 1977
    1976 Inhibition of 7,12-Dimethylbenz(a)anthracene-induced Mammary Carcinogenesis by Retinyl AcetateCancer Research.  36:2626-2630. 1976
    1976 Suppression of DMBA induced mammary tumorigenesis by retinyl methyl etherProceedings of the American Association for Cancer Research.  Vol. 17. 1976
    1976 The binding of benz(a)anthracene derivatives to glyceraldehyde-3-phosphate dehydrogenase and mammary tissue following exposure to laboratory lightChemico-Biological Interactions.  12:135-144. 1976
    1975 Binding of light exposed benz(a)anthracene (BA) derivatives to glyceraldehyde 3 phosphate dehydrogenase (GPDH) and mammary tissueProceedings of the American Association for Cancer Research.  16. 1975
    1975 Effect of age and parity upon the uptake of 9,10-dimethyl-1,2-benzanthracene-9-14C by mammary parenchymal cells of the ratBritish Journal of Cancer.  31:189-196. 1975
    1975 The inhibition of glyceraldehyde-3-phosphate dehydrogenase by benz(a)anthracene and its derivatives after exposure to laboratory lightingChemico-Biological Interactions.  10:173-183. 1975
    1974 Effect of light on the reaction of glyceraldehyde 3 phosphate dehydrogenase with DMBA derivativesProceedings of the American Association for Cancer Research.  Vol. 15:53. 1974
    1974 Uptake of progesterone-14C and estradiol-3H by isolated normal mammary parenchymal and cancer cells of the ratEuropean Journal of Cancer.  10:707-712. 1974
    1973 Transport of Orally Administered 9, 10-Dimethyl-1, 2-benzanthracene in the Sprague-Dawley RatCancer Research.  33:1785-1789. 1973
    1973 Uptake of estradiol 6,7 3H by isolated rat mammary parenchymal and tumor cells in vivo and in vitroFederation proceedings.  32:3419. 1973

    Education And Training

  • Master of Sciences or Mathematics in Biology, University of Tennessee System : Memphis 2000
  • Doctor of Philosophy in Medical Physiology, University of Tennessee System : Memphis 1973
  • Full Name

  • Clinton Grubbs